qPCR Assay, PDD & Benchtop Automation 2013 Market Trends ReportsnReports.com offers 2013 market research reports on trends in qPCR Assay, phenotypic drug discovery, benchtop automation and mass spectrometry (MS)-based screening assays.
DALLAS, May 1, 2013 /PRNewswire-iReach/ -- qPCR Assay Trends 2013, Phenotypic Drug Discovery Trends 2013, Benchtop Automation Trends 2013 and Mass Spec-Based Screening Assay Trends 2013 are new reports available with ReportsnReports.com
ReportsnReports.com now offers market research reports by HTStec Ltd. focusing on those enabling and emerging technologies that underpin high throughput screening (HTS) today. Here are the available 2013 trends reports and a brief from each:
The global market for qPCR thermal cyclers was estimated to be around $120M in 2013. The top 3 real time qPCR thermal cyclers respondents find most appealing to purchase were from ABI (Life Technologies), Bio-Rad and Roche. The sample prep instrumentation most used by respondents for adding cDNA or mastermixes when setting up qPCR assays was none i.e. manual hand pipettors were used. Most of these came mainly from Eppendorf and Gilson. The global market for qPCR assay consumables was estimated to be around $600M in 2013. The preferred supplier of qPCR reagent chemistries was Life Technologies. A median of 2 qPCR thermal cycling instruments were actively used in respondent's lab today. The thermal cycler most used in respondent's lab today was from ABI (Life Technologies). A median annual capex budget of $10K-$25K per lab per year was allocated for real time qPCR thermal cyclers today. This budget was expected to purchase a median of 1 unit. Complete report available @ http://www.reportsnreports.com/reports/238030-qpcr-assay-trends-2013.html.
The most preferred key vendors of assay reagents used in PDD were Life Technologies, Cell Signaling Technology, PerkinElmer and Sigma-Aldrich. The most preferred key vendors of instrument platforms used in PDD were PerkinElmer, Molecular Devices, GE Healthcare and Thermo Scientific. For the 102 validated responses for this survey, the assay type that best fits within respondent's definition/understanding of a phenotypic screening assay was 3D cell culture/2D co-culture assay models and target deconvolution was rated the main obstacle limiting adoption of phenotypic screening assays. Respondent's level of agreement with six controversial statements about PDD was recorded. Strongest agreement was recorded with the statement: 'PDD is a solid trend that bridges the in vitro to in vivo gap, it is likely to progress in primary screening over the next few years'. Strongest disagreement was recorded with the statement: 'PDD is being driven by upper management, not by the biology teams'. Complete report available @ http://www.reportsnreports.com/reports/238029-phenotypic-drug-discovery-trends-2013.html.
This survey collected 154 validated responses, of these 56% (87 out of 154) provided comprehensive input. Middle-level lab personnel were ranked as the greatest users of benchtop automation in respondent's lab. Respondents level of awareness in some selected benchop automation systems as highest for Tecan Freedom 75, Beckman Biomek BM3000, Qiagen QIAcube and Eppendorf epMotion 5070. The median annual capex budget for benchtop automation today (2013) was $5K-$10K. Based on the mean capex budgets and the % acquiring benchtop automation over the coming years the global market for benchtop automation was estimated to be around $175M in 2013. The market was segmented and CAGR estimates for 2015 made. The breakdown of the market into component automation categories was examined with the biggest proportion allocated to stand-alone automated pipettors/dispensers fed manually. The most appealing vendors of benchtop automation were Tecan, Beckman Coulter, Hamilton and Agilent. It was estimated that combined these 4 vendors had at least 40% market share. Most respondents expect to acquire a benchtop automation system over the next 3 years. Purchases were equally split between first time acquisition and adding new functionality/upgrading existing systems. The majority need a demo of a benchtop automation system at the time of purchase to see how it performs a specific method in order to reach a decision. A demo was most needed in the middle of the purchasing process i.e. when comparing a selection of vendors, some months prior to actual purchase. Complete report @ http://www.reportsnreports.com/reports/238031-benchtop-automation-trends-2013.html.
We also have a similar report on Mass Spec-Based Screening Assay Trends 2013. Explore more reports on Biotechnology industry @ http://www.reportsnreports.com/market-research/biotechnology/.
ReportsnReports.com is an online market research reports library of 250,000+ in-depth studies of over 5000 micro markets. Our database includes reports by leading publishers from across the globe. We provide 24/7 online and offline support service to our customers.
Media Contact: Priyank Tiwari ReportsnReports.com, +1 888 391 5441, email@example.com
News distributed by PR Newswire iReach: https://ireach.prnewswire.com